Skip to main content

Clinical Trials | A Phase 3, Randomized, Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator’s Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)

A Phase 3, Randomized, Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator’s Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)

The University of Virginia seeks adults ages 18 and over with Advanced Ovarian, Fallopian, or Peritoneal Cancer for a research study. You will be eligible if you have Low-Grade Serous Ovarian Cancer or LGSOC (ovarian, fallopian, peritoneal). The primary objective of this study is to compare the progression-free survival (PFS) of the combination of avutometinib plus defactinib vs. Investigator’s Choice of Treatment (ICT) in patients with recurrent LGSOC. The study drugs, called avutometinib and defactinib, are both a type of drug called a kinase inhibitor. Kinase inhibitors block cancer cell growth. You may be eligible for this study if you have: • Histologically proven LGSOC (ovarian, fallopian, peritoneal) • Progression or recurrence of LGSOC after at least one prior systemic therapy for metastatic disease. • Measurable disease according to RECIST v1.1. • An Eastern Cooperative Group (ECOG) performance status = 1. This study involves an ophthalmology exam, electrocardiogram (ECG), blood sampling, and CT scans. The study drug will be taken by mouth. Study-related procedures that are being done beyond your standard of care will be provided at no cost to you or your insurance. Study Details | A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer | ClinicalTrials.gov